Merck Proposes the Creation of a Global Alliance for the Elimination of Schistosomiasis
Merck proposed the creation of a global alliance to help the World Health Organization (WHO) achieve its goal of eliminating schistosomiasis worldwide in Geneva.
Merck is committed to helping WHO to eliminate the worm disease schistosomiasis in Africa. As an important part of its responsible entrepreneurship, the company launched the Merck Praziquantel Donation Program in 2007. Praziquantel is well tolerated and the most effective treatment to date for schistosomiasis. Since then, more than 38 million children have been treated and over 160 million tablets have been donated.
While other neglected tropical diseases have demonstrated the value of inclusive alliances, as of today no alliance for schistosomiasis yet exists. “We see this initiative as a major development,” said Oschmann. “This alliance will allow the different constituencies to engage in a coordinated approach to best address the challenges on how to meet the elimination target.” Merck will work with WHO and partners to define the appropriate structure of this alliance to ensure its pragmatic operational functionality.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
